PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 7, 2026Holistic Integrative Oncology0 citationsOpen Access

Analysis of acute genitourinary toxicity in hypofractionated proton beam therapy for localized prostate cancer

View Full Paper
WYWencui YangMedical Center HospitalJMJunetsu MizoeSapporo Science CenterYOYasuhiro OsakaSapporo Science Center

Key Points

  • To determine the incidence of grade 2 acute genitourinary toxicity after hypofractionated proton beam therapy for localized prostate cancer.
  • Patients received 51.6 Gy (RBE) delivered in 12 fractions over 3 weeks.
  • Neoadjuvant androgen deprivation therapy was administered based on risk classification.
  • The primary endpoint was the incidence of grade ≥ 2 acute GU toxicities within 3 months.
  • The incidence of grade 2 acute GU toxicities (urinary frequency) was 8%.
  • No grade ≥ 3 acute GU toxicities were observed.
  • Multivariate analysis confirmed high-risk classification associated with significantly lower risk of grade 2 GU toxicities.

Abstract

Abstract Purpose To prospectively determine the incidence of grade 2 acute genitourinary (GU) toxicity after hypofractionated proton beam therapy (PBT) for localized prostate cancer. Methods The protocol was approved by the institutional review board (IRB). Patients received 51.6 Gy (relative biological effectiveness (RBE)) delivered in 12 fractions over 3 weeks. The primary endpoint was the incidence of grade ≥ 2 acute GU toxicities within 3 months. Neoadjuvant androgen deprivation therapy (ADT) was administered to the intermediate-risk group, and neoadjuvant and adjuvant ADT were administered to high-risk group classified according to the National Comprehensive Cancer Network (NCCN) guideline. Results From March 2021 to June 2024, 100 patients underwent hypofractionated PBT. The incidence of grade 2 acute GU toxicities (urinary frequency) was 8% (95% confidence interval CI 2.6–13.4), meeting the pre-specified continuation criterion. No grade ≥ 3 acute GU toxicities were observed. Furthermore, no grade ≥ 2 acute urinary retention, urinary pain, urinary urgency or hematuria were observed. Univariate analysis preliminarily suggested that compared with the high-risk group patients, the low- and/or intermediate-risk group patients had a higher trend of grade 2 GU toxicities (OR: 0.265 (95% CI 0.066–1.062), P = 0.055). Multivariate regression analysis further confirmed that the high-risk classification was associated with a significantly lower risk grade 2 GU toxicities (OR: 0.023 (95% CI 0.002–0.840), P = 0.042). Additionally, multivariate regression analysis confirmed that benign prostatic hyperplasia (BPH) was an independent influencing factor for grade 2 GU toxicity (OR: 0.040 (95% CI 0.003–0.582), P = 0.018). Conclusions Our results indicate that hypofractionated PBT (51.6 Gy RBE in 12 fractions over 3 weeks) for localized prostate cancer provides acceptable acute GU toxicity rates. Long-term follow-up of the 300-patient expansion cohort is underway to evaluate late toxicities and long-term oncological efficacy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Yang et al. (2026) studied this question.

synapsesocial.com/papers/69fbf004164b5133a91a437bhttps://doi.org/10.1007/s44178-026-00246-z
Ask AI
Helpful
Bookmark
Share
View Full Paper